Please select the option that best describes you:
Topics:
Rheumatology • Rheumatoid Arthritis • Vasculitis • Rituximab • General Rheumatology • Oncology
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
Does your approach differ based on the underlying condition - such as ANCA-associated vasculitis, rheumatoid arthritis, or another autoimmune disease?